Pre-clinical models of renal carcinoma and their utility in drug development

Brenda C. Salumbides, Kristin M. Lehet, Georges Ndikuyeze, Roberto Pili

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Significant progress has been made in the treatment of patients with advanced renal cancer. In addition to immunotherapy, there are several potentially distinct therapeutic approaches for targeting molecular pathways. The murine models detailed in this unit are useful for testing rational combination strategies. Moreover, animal models contribute immensely to the understanding of the genetic, epigenetic, and biological aspects of human disease. Compared to humans, rodent models are relatively short-lived and allow for the facile study of clinically relevant pathologies. Animal models for the study of renal cell carcinoma (RCC) are particularly useful for the development of new drugs for kidney cancer. Included in this unit are several in vivo models that are currently used to evaluate therapeutic approaches to renal cancer therapy and to investigate the pathophysiology of this condition. Included are both murine (RENCA) and renal cell carcinomas in subcutaneous and orthotopic models using tumor cell lines and human tumor tissue.

Original languageEnglish (US)
JournalCurrent Protocols in Pharmacology
Issue numberSUPPL.47
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Kidney Neoplasms
Carcinoma
Kidney
Renal Cell Carcinoma
Pharmaceutical Preparations
Animal Models
Therapeutics
Tumor Cell Line
Epigenomics
Immunotherapy
Rodentia
Pathology
Neoplasms

Keywords

  • Angiogenesis
  • Bioluminescent imaging
  • Combination therapy
  • Immunotherapy
  • Metastastic tumor
  • Orthotopic implantation
  • Renal cell carcinoma
  • Retinoids
  • Subcutaneous implantation
  • Xenograft model

ASJC Scopus subject areas

  • Pharmacology

Cite this

Pre-clinical models of renal carcinoma and their utility in drug development. / Salumbides, Brenda C.; Lehet, Kristin M.; Ndikuyeze, Georges; Pili, Roberto.

In: Current Protocols in Pharmacology, No. SUPPL.47, 2009.

Research output: Contribution to journalReview article

Salumbides, Brenda C. ; Lehet, Kristin M. ; Ndikuyeze, Georges ; Pili, Roberto. / Pre-clinical models of renal carcinoma and their utility in drug development. In: Current Protocols in Pharmacology. 2009 ; No. SUPPL.47.
@article{f0027bd5609b4606beda4f67b2ee6fb6,
title = "Pre-clinical models of renal carcinoma and their utility in drug development",
abstract = "Significant progress has been made in the treatment of patients with advanced renal cancer. In addition to immunotherapy, there are several potentially distinct therapeutic approaches for targeting molecular pathways. The murine models detailed in this unit are useful for testing rational combination strategies. Moreover, animal models contribute immensely to the understanding of the genetic, epigenetic, and biological aspects of human disease. Compared to humans, rodent models are relatively short-lived and allow for the facile study of clinically relevant pathologies. Animal models for the study of renal cell carcinoma (RCC) are particularly useful for the development of new drugs for kidney cancer. Included in this unit are several in vivo models that are currently used to evaluate therapeutic approaches to renal cancer therapy and to investigate the pathophysiology of this condition. Included are both murine (RENCA) and renal cell carcinomas in subcutaneous and orthotopic models using tumor cell lines and human tumor tissue.",
keywords = "Angiogenesis, Bioluminescent imaging, Combination therapy, Immunotherapy, Metastastic tumor, Orthotopic implantation, Renal cell carcinoma, Retinoids, Subcutaneous implantation, Xenograft model",
author = "Salumbides, {Brenda C.} and Lehet, {Kristin M.} and Georges Ndikuyeze and Roberto Pili",
year = "2009",
doi = "10.1002/0471141755.ph1413s47",
language = "English (US)",
journal = "Current Protocols in Pharmacology",
issn = "1934-8282",
publisher = "John Wiley and Sons Inc.",
number = "SUPPL.47",

}

TY - JOUR

T1 - Pre-clinical models of renal carcinoma and their utility in drug development

AU - Salumbides, Brenda C.

AU - Lehet, Kristin M.

AU - Ndikuyeze, Georges

AU - Pili, Roberto

PY - 2009

Y1 - 2009

N2 - Significant progress has been made in the treatment of patients with advanced renal cancer. In addition to immunotherapy, there are several potentially distinct therapeutic approaches for targeting molecular pathways. The murine models detailed in this unit are useful for testing rational combination strategies. Moreover, animal models contribute immensely to the understanding of the genetic, epigenetic, and biological aspects of human disease. Compared to humans, rodent models are relatively short-lived and allow for the facile study of clinically relevant pathologies. Animal models for the study of renal cell carcinoma (RCC) are particularly useful for the development of new drugs for kidney cancer. Included in this unit are several in vivo models that are currently used to evaluate therapeutic approaches to renal cancer therapy and to investigate the pathophysiology of this condition. Included are both murine (RENCA) and renal cell carcinomas in subcutaneous and orthotopic models using tumor cell lines and human tumor tissue.

AB - Significant progress has been made in the treatment of patients with advanced renal cancer. In addition to immunotherapy, there are several potentially distinct therapeutic approaches for targeting molecular pathways. The murine models detailed in this unit are useful for testing rational combination strategies. Moreover, animal models contribute immensely to the understanding of the genetic, epigenetic, and biological aspects of human disease. Compared to humans, rodent models are relatively short-lived and allow for the facile study of clinically relevant pathologies. Animal models for the study of renal cell carcinoma (RCC) are particularly useful for the development of new drugs for kidney cancer. Included in this unit are several in vivo models that are currently used to evaluate therapeutic approaches to renal cancer therapy and to investigate the pathophysiology of this condition. Included are both murine (RENCA) and renal cell carcinomas in subcutaneous and orthotopic models using tumor cell lines and human tumor tissue.

KW - Angiogenesis

KW - Bioluminescent imaging

KW - Combination therapy

KW - Immunotherapy

KW - Metastastic tumor

KW - Orthotopic implantation

KW - Renal cell carcinoma

KW - Retinoids

KW - Subcutaneous implantation

KW - Xenograft model

UR - http://www.scopus.com/inward/record.url?scp=75949129172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75949129172&partnerID=8YFLogxK

U2 - 10.1002/0471141755.ph1413s47

DO - 10.1002/0471141755.ph1413s47

M3 - Review article

JO - Current Protocols in Pharmacology

JF - Current Protocols in Pharmacology

SN - 1934-8282

IS - SUPPL.47

ER -